ENTITY CLASS
Growth-hormone-axis peptides
GHRH analogs and growth-hormone secretagogues with sharply different clinical and regulatory histories.
CONNECTED RECORDS
Growth-hormone-axis peptides: evidence by entity.
Peptide analogHuman evidence 5/5
Tesamorelin
Tesamorelin has the strongest human evidence in a narrow, labeled population. Evidence from that population should not be generalized to routine weight management.
Open evidence recordPeptide analogHuman evidence 2/5
Sermorelin
Sermorelin has a longer clinical history than many wellness-market peptides, but historical use is not the same as a current approved product or modern outcomes evidence.
Open evidence recordPeptide analogHuman evidence 2/5
CJC-1295
CJC-1295 can produce measurable endocrine effects, but biomarker changes should not be confused with proven improvement in health outcomes.
Open evidence recordSynthetic peptideHuman evidence 2/5
Ipamorelin
Ipamorelin has human exposure data, but the evidence base is narrow and does not validate generalized anti-aging or body-composition claims.
Open evidence record